FDA Lifts Clinical Hold on Filana Therapeutics' Epilepsy Drug Simufilam

Key Facts

1The U.S. FDA lifted the clinical hold on simufilam, enabling the initiation of a Phase 2a proof-of-concept study.

2The study targets patients aged 12 to 55 with Tuberous Sclerosis Complex (TSC)-related epilepsy.

3Patient screening for the clinical study is expected to begin by the first quarter of 2027.

In a move reflecting a significant regulatory breakthrough for the biotech sector, Filana Therapeutics announced that the U.S. FDA has lifted the clinical hold on its investigational drug simufilam. This decision enables the company to initiate a planned Phase 2a proof-of-concept study targeting patients aged 12 to 55 with Tuberous Sclerosis Complex (TSC)-related epilepsy. According to reports, patient screening for the clinical study is expected to commence by the first quarter of 2027.

The lifting of the hold follows the FDA's review of the company's investigational new drug application, removing a primary obstacle to its clinical development path. This milestone is critical as the company seeks to address drug-resistant epilepsy, which remains a challenge for the majority of individuals affected by TSC. Per market data, the stock FLNA stood at 0.7395 USD at the close of September 21, 2026, having reached a day high of 0.767 USD.

Looking ahead, investors will monitor the company's ability to execute its development plan and begin enrollment as scheduled in early 2027. Based on price levels at the close of September 21, 2026, the stock maintains a position above its daily low of 0.7288 USD. With no immediate major pharmaceutical catalysts in the upcoming economic calendar, focus remains on the company's internal regulatory timelines and clinical milestones.